Erdheim-Chester Disease

Histiocytic disorders are a group of rare disorders characterised by the abnormal accumulation of histiocytes, a type of immune cell often found in tissues that regulates immune functions. There are three primary types of histiocytes, including monocytes (plays a role in inflammatory and anti-inflammatory responses during an immune response), macrophages (responsible for ingesting and eliminating foreign substances during an immune reaction), and dendritic cells (initiate and regulate the adaptive immune response).

Histiocytic disorders are broadly classified into five different groups: L groupC groupM groupR group, and H group. The L group, or Langerhans group, are classified as diseases involving Langerhans cells (an immune cell responsible for initiating an immune response when coming into contact with a foreign material), such as Langerhans cell histiocytosis (LCH). The C group, also known as cutaneous and mucocutaneous non-Langerhans cell histiocytosis, are classified as non-Langerhans cell histiocytic disorders that are localised to the skin or mucosal surfaces, such as the mouth, nose, and gastrointestinal system. The M group, also known as malignant histiocytic disorders, are classified by the presence of malignant cells within the tumour(s). The R group, also known as Rosai-Dorfman disease and miscellaneous non-cutaneous non-Langerhans cell histiocytosis or sinus histiocytosis, are classified as non-Langerhans histiocytic disorders that often involve lymph nodes. The H group, also known as hemophagocytic lymphocytosis and macrophage activation syndrome, is composed entirely of hemophagocytic lymphohistiocytosis, a rare and aggressive disease caused by the overactivation of the immune system.

This page will focus on Erdheim-Chester disease (ECD), a common subtype of L group histiocytic disorder. It is defined as a is a rare cancer-like disorder that causes an abnormal increase in a type of white blood cell (WBC) called histiocytes, which play a significant role in many vital immune functions. It is most commonly found as lesions on the long bones of the legs, however it can also develop in the cardiovascular system, central nervous system (CNS), and other organs within the body. ECD often affects many systems within the body.

ECD is slightly more common in men, and is generally diagnosed between the ages of 50 and 60. However, anyone can develop this disease.

Treatment

Each patient with ECD will present with a unique disease behaviour, with varying locations, and symptoms. As such, there is no one treatment method that will work for everyone, and there is no standard staging system for this disease.  Instead of staging and grading, your doctor will recommend a treatment plan based on the following factors:

  • Cancer location.
  • Whether or not the cancer has metastasised.
  • Your age.
  • General health.
  • Your treatment preferences.

Your doctor may recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. Your doctor will discuss the most appropriate course of treatment for you.

Treatment options for patients with ECD may include:

  • Watch and wait (may be an option for some asymptomatic patients).
  • Corticosteroids.
  • Chemotherapy.
  • Radiation therapy.
  • Immunotherapy.
  • Targeted therapy.
  • Surgery to remove as much of the tumour as possible.
  • Clinical trials.
  • Palliative care.

Risk factors

Because of how rare ECD is, there has been limited research done into the risk factors of this disease. However, a genetic mutation in the BRAF gene (a protein involved in the sending of chemical signals between cells and cell growth) has been identified in a significant portion of people with this disease.

Symptoms

The symptoms of ECD will vary depending on the location(s) of the disease.

General Symptoms of ECD

General symptoms of ECD may include:

  • Weight loss.
  • Fever.
  • Fatigue.
  • Muscle and/or joint aches.
  • General feeling of discomfort.
  • Weakness.

ECD affecting bones

Most patients with ECD will experience some changes in the bones.  In addition to the general symptoms listed above, patients with ECD in the bones may experience some of the following symptoms:

  • Osteosclerosis.
  • Bone pain in affected area.
  • Bone lesions.

ECD affecting the Cardiovascular System

In addition to the general symptoms listed above, patients with ECD in the cardiovascular system (such as the heart, pericardium, and aorta (the largest artery in the body)) may experience some of the following symptoms:

  • Heart valve abnormalities.
  • Heart rhythm abnormalities.
  • Heart conduction defects.
  • Periaortic fibrosis (inflammation of the aorta).
  • Pericardial effusion.
  • Myocardial infarctions (heart attacks).
  • Cardiomyopathy.

ECD affecting the CNS

In addition to the general symptoms listed above, patients with ECD in the CNS (including the dura (connective tissue surrounding the brain and spinal cord), pituitary gland (one of the primary endocrine glands of the body), other regions of the brain and/or spinal cord) may also experience some of the following symptoms:

  • Diabetes insipidus (a disorder causing a fluid imbalance in the body).
  • Polyuria.
  • Polydipsia.
  • Impaired muscle coordination.
  • Difficulties walking.
  • Slurred speech.
  • Involuntary, rapid eye movements.
  • Hormone imbalances.
  • Loss of libido.
  • Headache.
  • Seizures.
  • Changes in behaviour.
  • Difficulty concentrating.
  • Spinal cord compression.

ECD affecting Retro-orbital Tissues

In addition to the general symptoms listed above, patients with ECD in retro-orbital tissues (the tissues behind the eyes) may also experience some of the following symptoms:

  • Pain behind the eyes.
  • Proptosis.
  • Blindness.

ECD affecting the Skin

In addition to the general symptoms listed above, patients with ECD in the skin may also experience some of the following symptoms:

  • Yellow plaques under the skin (most commonly on the eyelids).
  • Reddish-brown nodules on the skin.

ECD affecting the Lungs

In addition to the general symptoms listed above, patients with ECD in the lungs may also experience some of the following symptoms:

  • Pulmonary fibrosis (progressive scarring and thickening of lung tissue).
  • Dry cough.
  • Dyspnea.
  • Decreased breathing output.

ECD affecting the Retroperitoneum

In addition to the general symptoms listed above, patients with ECD in the retroperitoneum may also experience some of the following symptoms:

  • Ureteral obstruction (blockage of ureters – the tubes that carry urine from the kidneys to the bladder).
  • Abdominal swelling.
  • Impaired kidney function.
  • Renal failure (in extreme cases).

Not everyone with the symptoms above will have cancer, but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have ECD, they may order the following tests to confirm the diagnosis and refer you to a specialist for treatment:

  • Physical examination.
  • Neurological examination.
  • Blood tests.
  • Urine tests.
  • Imaging tests, potentially including:
    • X-ray.
    • MRI (magnetic resonance imaging).
    • CT (computed tomography) scan.
    • PET (positron emission tomography) scan.
    • Bone scan.
  • Pulmonary function test.
  • Bone marrow aspiration.
  • Exploratory surgery, potentially including:
    • Endoscopy.
    • Bronchoscopy.
  • Biopsy.

References

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.